The Impact of Treatment with Guselkumab on Skin-related Quality of Life in Male and Female Patients with Moderate to Severe Psoriasis: Results from the VOYAGE 1 and 2 Trials

被引：0
|
作者：
Armstrong, April [1 ]
Puig, Luis [2 ]
Papp, Kim A. [3 ]
Strauss, Marcie E. [4 ]
Yang, Ya-Wen [5 ]
Cheng, Ru-Fong [6 ]
Miller, Megan [7 ]
Murase, Jenny E. [8 ,9 ]
Fernandez-Penas, Pablo [10 ]
Han, Chenglong [11 ]
机构：
[1] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA
[2] Autonomous Univ Barcelona, Hosp Santa Creu & Sant Pau, Barcelona, Spain
[3] K Papp Clin Res & Prob Res Inc, Waterloo, ON, Canada
[4] MEDASOURCE, Indianapolis, IN USA
[5] Janssen Pharmaceut Co Johnson & Johnson, Immunol Global Med Affairs, Horsham, PA USA
[6] Johnson & Johnson, Womens Hlth, Chief Med Off, New Brunswick, NJ USA
[7] Janssen Res & Dev LLC, Spring House, PA USA
[8] Univ Calif San Francisco, San Francisco, CA USA
[9] Palo Alto Fdn Med Grp, Mountain View, CA USA
[10] Westmead Hosp, Sydney Med Sch, Dept Dermatol, Westmead, NSW, Australia
[11] Janssen Global Serv LLC, Malvern, PA USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：AB235 / AB235
页数：1
相关论文
共 50 条
  • [1] Characterization of super responders to guselkumab treatment in moderate to severe psoriasis: Results from the VOYAGE 1 and 2 clinical trials
    Reich, Kristian
    Strober, Bruce
    Langley, Richard
    Song, Michael
    Shen, Yaung-Kaung
    You, Yin
    Foley, Peter
    Blauvelt, Andrew
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB145 - AB145
  • [2] Characterization of super responders to guselkumab treatment in moderate-to-severe psoriasis: results from the VOYAGE 1 and 2 clinical trials
    Reich, K.
    Gordon, K. B.
    Strober, B.
    Langley, R. G.
    Song, M.
    Shen, Y-K
    You, Y.
    Foley, P.
    Blauvelt, A.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2021, 62 : 55 - 56
  • [3] Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2
    Reich, K.
    Gordon, K. B.
    Strober, B. E.
    Armstrong, A. W.
    Miller, M.
    Shen, Y. K.
    You, Y.
    Han, C.
    Yang, Y. W.
    Foley, P.
    Griffiths, C. E. M.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (06) : 1146 - 1159
  • [4] Consistency of response (PASI 90 or 100 and IGA 0 or 0/1) in patients with moderate to severe psoriasis treated with guselkumab: Results from the VOYAGE 1 and 2 trials
    Gordon, Kenneth
    Menter, Alan
    Ferris, Laura
    Martorell, Antonio
    Kim, Byung Soo
    Song, Michael
    Wasfi, Yasmine
    You, Yin
    Shen, Yaung-Kaung
    Langley, Richard
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB87 - AB87
  • [5] Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two Phase 3 trials
    Guenther, L.
    Warren, R. B.
    Cather, J. C.
    Sofen, H.
    Poulin, Y.
    Lebwohl, M.
    Terui, T.
    Bleakman, A. Potts
    Zhu, B.
    Burge, R.
    Reich, K.
    van de Kerkhof, P.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (11) : 1867 - 1875
  • [6] Mediation analysis of independent treatment effect of guselkumab on health-related quality of life in patients with moderate to severe plaque-type psoriasis: Results from 2 phase 3 studies VOYAGE-1&2
    Armstrong, April W.
    Liu, Yan
    Li, Nan
    Reich, Kristian
    Foley, Peter
    Li, Shu
    Fakharzadeh, Steven
    Papp, Kim A.
    Han, Chenglong
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB128 - AB128
  • [7] Secukinumab provides more effective relief from skin-related quality-of-life impact than etanercept in moderate to severe psoriasis
    Tyring, Stephen
    Sofen, Howard
    Fretzin, Scott
    Rich, Phoebe
    Zhao, Yang
    Herrera, Vivian
    Sherif, Bintu
    Williams, Nicole
    Nyirady, Judit
    Korman, Neil
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB272 - AB272
  • [8] Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials
    Blauvelt, Andrew
    Lebwohl, Mark
    Langley, Richard G.
    Rowland, Katelyn
    Yang, Ya-Wen
    Chan, Daphne
    Miller, Megan
    You, Yin
    Yu, Jenny
    Thaci, Diamant
    Foley, Peter
    Papp, Kim A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (02) : 274 - 282
  • [9] Ixekizumab impact on the skin-related relationship problems of patients with moderate-to-severe plaque psoriasis: integrated results from three Phase 3 trials (UNCOVER-1,-2,-3)
    Warren, R. B.
    Cather, J.
    Ohtsuki, M.
    Bleakman, A. Potts
    Burge, R.
    Zhu, B.
    Reich, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 77 - 78
  • [10] Immunogenicity and pharmacokinetics of guselkumab among patients with moderate-to-severe psoriasis in VOYAGE-1 and VOYAGE-2
    Armstrong, A.
    Eyerich, K.
    Conrad, C.
    Zhu, Y.
    Yang, Y. -w.
    Miller, M.
    You, Y.
    Shen, Y. -k.
    Foley, P.
    Griffiths, C. E. M.
    Strober, B.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (12) : E1375 - E1379
12345